AIM ImmunoTech Files S-1 for Public Offering

TL;DR

AIM ImmunoTech filed an S-1, looks like they're raising cash soon.

AI Summary

AIM ImmunoTech Inc. filed an S-1 registration statement on July 11, 2024, to potentially offer securities to the public. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and headquartered in Ocala, Florida. This filing indicates a step towards raising capital, though specific dollar amounts and offering details are not yet provided in this initial document.

Why It Matters

This S-1 filing signals AIM ImmunoTech's intention to access public markets for capital, which could fund its research and development efforts in immuno-oncology and other therapeutic areas.

Risk Assessment

Risk Level: medium — S-1 filings indicate a company is seeking to raise capital, which can be a positive sign but also carries inherent risks associated with public offerings and the company's specific stage of development.

Key Numbers

• 333-280761 — SEC File Number (Identifies the specific SEC registration file for this offering.)
• 0000946644 — Central Index Key (Unique identifier for AIM ImmunoTech Inc. in SEC filings.)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Registrant
• July 11, 2024 (date) — Filing Date
• Hemispherx Biopharma Inc. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• Ocala, Florida (location) — Principal Executive Offices
• Thomas K. Equels (person) — Chief Executive Officer
• Richard Feiner, Esq. (person) — Agent for Service Counsel

FAQ

Key Financial Figures

• $0.001 — 1,916 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $0.359 — r Common Stock on the NYSE American was $0.359 per share. Investing in our Common St
• $250 million — y, and have a public float of less than $250 million or annual revenues of less than $100 mi
• $100 million — million or annual revenues of less than $100 million during the most recently completed fisc
• $19.66 — at a weighted average exercise price of $19.66 per share; and 2,814,142 shares of our
• $1.54 — at a weighted average exercise price of $1.54 per share; 2,353,019 shares of our Co
• $4,095,336 — for cash, we will receive approximately $4,095,336 in gross proceeds. We will bear the o

Filing Documents

• forms-1.htm (S-1) — 487KB
• ex5-1.htm (EX-5.1) — 25KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107-1.htm (EX-FILING FEES) — 18KB
• forms-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-027002.txt ( ) — 540KB

USE OF PROCEEDS

USE OF PROCEEDS 3 DIVIDEND POLICY 3 DETERMINATION OF THE OFFERING PRICE 3

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 3 DESCRIPTION OF THE PRIVATE PLACEMENT 5 SELLING STOCKHOLDER 6 PLAN OF DISTRIBUTION 8 LEGAL MATTERS 9 EXPERTS 9 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 9 WHERE YOU CAN FIND MORE INFORMATION 9 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus and any related free writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. This prospectus and the documents incorporated by reference into this prospectus include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by AIM, by third parties, or by third parties in collaboration with AIM. Industry publications and research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that the data obt

View Full Filing

View this S-1 filing on SEC EDGAR